Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SPECT scan Clear all
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

NCT04090398
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Paclitaxel, Radium Ra 223 Dichloride, Single Photon Emission Computed Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

NCT03011320
View directory record Official record
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Not applicable Interventional Results available

Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events

NCT03183063
View directory record Official record
Conditions
Pulmonary Thromboembolisms, Pulmonary Embolism
Interventions
4DCT and SPECT/CT, 4DCT with BiPAP and SPECT/CT, 4DCT with CTA in suspected PE
Device
Lead sponsor
Thomas Guerrero
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 21, 2026, 9:23 PM EDT
Not listed No phase listed Observational

Validation of DaTscan for Detection of Parkinson Disease Related Disorders

NCT02138682
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
l-123 Ioflupane
Drug
Lead sponsor
Wisconsin Institute for Neurologic and Sleep Disorders S.C.
Industry
Eligibility
75 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Not applicable Interventional Results available

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

NCT01982123
View directory record Official record
Conditions
Lung Carcinoma, Malignant Neoplasm
Interventions
SPECT/CT, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m DTPA
Diagnostic Test · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 21, 2026, 9:23 PM EDT
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 21, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 9:23 PM EDT
Active, not recruiting Phase 1 Interventional Results available

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

NCT03120624
View directory record Official record
Conditions
Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Stage IV Uterine Corpus Cancer AJCC v7
Interventions
Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate, Pharmacological Study, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Ruxolitinib Phosphate, Technetium Tc-99m Sodium Pertechnetate, Biospecimen Collection
Procedure · Other · Biological + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Terminated Phase 2 Interventional Results available

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

NCT01886105
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy
Drug · Other · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
10 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Phase 1 of EC1169 In Patients With Recurrent MCRPC

NCT02202447
View directory record Official record
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 21, 2026, 9:23 PM EDT
Completed No phase listed Observational

Functional Imaging in Lung SBRT

NCT03121300
View directory record Official record
Conditions
Lung Cancer
Interventions
CT Scan, Lung CT, MRI, Walk Test, SGRQ, Biological Sample Collection, Toxicity, Cardiac Assessment
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 21, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

NCT03619655
View directory record Official record
Conditions
Prostate Cancer
Interventions
SPECT CT, 18F-DCFPyL PET/CT, 18F-NaF PET/CT, WB-MRI
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 9:23 PM EDT
Recruiting Phase 1 Interventional

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

NCT05901545
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Surgical Procedure, Imaging agent, Intraoperative Imaging, Near Infrared Imaging, Electrocardiography, Biospecimen Collection
Biological · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.

NCT01859767
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[123I]MNI-672 SPECT
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

NCT00321048
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
Interventions
Active Breathing Coordinator
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 21, 2026, 9:23 PM EDT
Completed Phase 1 Interventional

Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy

NCT06665633
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Hyperbaric Oxygen Therapy, Depression
Interventions
Oxygen 100 % Gas for Inhalation, Hyperbaric Oxygen Therapy Chamber
Drug · Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 9:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

NCT05891769
View directory record Official record
Conditions
Parathyroid Adenoma
Interventions
18Fluorocholine
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537
View directory record Official record
Conditions
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions
Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
106
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 9:23 PM EDT
Withdrawn Phase 3 Interventional

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395
View directory record Official record
Conditions
Fever of Unknown Origin
Interventions
68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT
Drug · Device
Lead sponsor
Carina Mari Aparici
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 21, 2026, 9:23 PM EDT
Active, not recruiting Early Phase 1 Interventional

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

NCT05111509
View directory record Official record
Conditions
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
Interventions
[203Pb]VMT-α-NET, SPECT/CT
Drug · Device
Lead sponsor
Yusuf Menda
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 9:23 PM EDT